revive-therapeutics.png
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
06 juil. 2023 06h30 HE | Revive Therapeutics Ltd.
TORONTO, July 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Dopavision gibt Update zur klinischen Studie mit MyopiaX® bekannt; alle Studienzentren aktiv
28 juin 2023 04h00 HE | AKAMPION
- Klinische Erprobung von MyopiaX®, dem ersten Ansatz zur digitalen Behandlung von Kurzsichtigkeit bei Kindern beruhend auf dem Dopamin-Signalweg - Aufnahme von Patienten in Deutschland, Spanien,...
Dopavision proporciona información actualizada sobre los ensayos clínicos y anuncia que todos los centros del ensayo MyopiaX-1 están activos
28 juin 2023 04h00 HE | AKAMPION
- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania, España, Países...
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
28 juin 2023 04h00 HE | AKAMPION
- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the...
revive-therapeutics.png
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
30 mai 2023 07h30 HE | Revive Therapeutics Ltd.
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
22 mai 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
Low Loss Fill Process at Berkshire Sterile Manufacturing
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight
18 mai 2023 13h00 HE | Berkshire Sterile Manufacturing
Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...
SPR Therapeutics LOGO 361 TM.jpg
Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS
17 mai 2023 10h16 HE | SPR Therapeutics, Inc.
CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant...
revive-therapeutics.png
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
12 mai 2023 07h00 HE | Revive Therapeutics Ltd.
TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
09 mai 2023 03h30 HE | AKAMPION
Data presented at RACS 91st Annual Scientific Congress 2023Initial findings demonstrate that BellaSeno’s resorbable implants are safe, well tolerated and lead to natural tissue growth Leipzig,...